New drug cocktail shows promise for Hard-to-Treat myeloma
NCT ID NCT03180736
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase 3 study tested whether adding daratumumab to the standard two-drug regimen (pomalidomide and dexamethasone) could help people with relapsed or refractory multiple myeloma live longer without their cancer worsening. The trial enrolled 304 adults who had already tried at least one prior therapy. The main goal was to compare progression-free survival between the two treatment groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ancona
Ancona, Italy
-
Anticancer Hospital of Thessaloniki "Theageneio"
Thessaloniki, Greece
-
Antwerpen
Antwerp, Belgium
-
Badalona
Badalona, Spain
-
Barcelona
Barcelona, Spain
-
Belgrade
Belgrade, Serbia
-
Bologna
Bologna, Italy
-
Brescia
Brescia, Italy
-
Brno
Brno, Czechia
-
Brussel
Brussels, Belgium
-
Capa
Çapa, Turkey (Türkiye)
-
Cebeci
Cebeli, Turkey (Türkiye)
-
Doctor Peset University Hospital Medical Centre
Valencia, Spain
-
Erasmus MC
Rotterdam, Netherlands
-
Freiburg
Freiburg im Breisgau, Germany
-
Gaziantep
Gaziantep, Turkey (Türkiye)
-
General Hospital of Athens "Evangelismos"
Athens, Greece
-
General University Hospital of Patras
Pátrai, Greece
-
Hamburg
Hamburg, Germany
-
Heidelberg
Heidelberg, Germany
-
Hospital Quirón Salud Madrid
Madrid, Spain
-
Hospital Universitario de la Princesa
Madrid, Spain
-
Izmir
Izmir, Turkey (Türkiye)
-
Kayseri
Kayseri, Turkey (Türkiye)
-
Kiel
Kiel, Germany
-
Milano
Milan, Italy
-
Odense
Odense, Denmark
-
Ostrava
Ostrava, Czechia
-
Praha 2
Prague, Czechia
-
Roma
Roma, Italy
-
Salamanca University Hospital
Salamanca, Spain
-
Schwerin
Schwerin, Germany
-
Torino
Torino, Italy
-
Tübingen
Tübingen, Germany
-
UZ Gent
Ghent, Belgium
-
University of Athens School of Medicine
Athens, Greece
-
VU MC
Amsterdam, Netherlands
-
Vejle
Vejle, Denmark
-
Würzburg
Würzburg, Germany
-
Yvoir
Yvoir, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab (a targeted antibody), pomalidomide (a cancer drug), and dexamethasone (a steroid)
What this could lead to
If successful, this combination could offer a new, more effective treatment option for people with multiple myeloma that has returned or stopped responding to prior therapies.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all patients. Side effects from the drugs, including infusion reactions and infections, are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.